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Abstract 
Review on CASP8, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: ALPS2B, CAP4, Casp-8, FLICE, 
MACH, MCH5 
HGNC (Hugo): CASP8 
Location: 2q33.1 
Local order: CASP8 is located on chromosome 2 
on the long arm (positive strand), and lies between 
the CASP10 and STRADB genes. 
DNA/RNA 
Description 
54269 bases with 11 exons. 
Transcription 
There are 6 transcriptional variants of CASP8 and  
 
 
they are described in Table 1. 
Protein 
Note 
Caspases are a family of cysteinyl aspartate specific 
proteases which are synthesized as zymogens. 
Caspase-8 was discovered as a component of the 
CD95 (Fas/APO-1) death-inducing signaling 
complex (DISC) (Muzio et al., 1996). 
Description 
Caspase-8 has a number of isoforms, including 
procaspase-8a (496 aa), procaspase-8b (479 aa), 
procaspase-8c (464 aa), procaspase-8e (235 aa), 
procaspase-8g or caspase-8L (538 aa) and caspase-
8 short (108 aa). 
Only two isoforms are predominantly expressed in 
many different tissues and cell lines: procaspase-8a 
and procaspase-8b (Scaffidi et al., 1997). 
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Caspase-8L was reported to be expressed in human 
peripheral blood lymphocytes as a truncated 
protein, which lacks the C-terminal protease 
domain (Horiuchi et al., 2000).  
Therefore, it is suggested that caspase-8L is 
recruited into the DISC but remains proteolytically 
inert, interfering with the transduction of the signal 
from the DISC (Himeji et al., 2002). 
An isoform that is detected in bone marrow 
mononuclear cells is named caspase-8 short. 
Although it only contains the first DED and a part 
of the second DED, overexpression of caspase-8 
short is reported to increase sensitivity to apoptosis 
(Xu et al., 2009). 
In addition to caspase-8 isoforms, there is a number 
of cleavage products described, which are formed 
in the course of apoptosis.  
Apoptotic processing of procaspase-8a/b involves 
generation of the cleavage products p43/p41, p30, 
the prodomains p26/p24, p18 and p10 (Hoffmann et 
al., 2009).  
The latter two cleavage products form the active 
caspase-8 heterotetramer p102-p182 that triggers 
apoptosis (Lavrik and Krammer, 2012). 
Expression 
Caspase-8 is expressed in almost all kind of tissues, 
with the highest expression in the immune system 
and lowest in the nervous system (McCall et al., 
2011). 
Localisation 
Procaspase-8 mainly localizes to the cytosol, in 
close proximity to the membrane (Medema et al., 
1997).  
It may also localize to mitochondria (Qin et al., 
2001; Chandra et al., 2004) or centrosomes (Mielgo 
et al., 2009).  
Caspase-8 cleavage products are reported to 
localize to the nucleus as well as the cytosol 
(Benchoua et al., 2002; Yao et al., 2007). 
Function 
Caspase-8 is the main initiator caspase in death 
receptor-induced apoptosis.  
Upon stimulation, procaspase-8 is recruited to the 
CD95 or TRAIL DISC, or TNF complex II. 
Procaspase-8 activation involves dimerization, 
oligomerization and cleavage (Schleich et al., 
2012).  
The cleavage of procaspase-8 involves several 
steps, leading to the generation of the active 
caspase-8 heterotetramer p102-p182 (Lavrik and 
Krammer, 2012).  
Depending on the cell type, active caspase-8 either 
directly cleaves effector caspases (caspase-3 and 
caspase-7) or cleaves Bid, which eventually leads to 
release of cytochrome C and apoptosome formation 
followed by cleavage of effector caspase-3, 
caspase-6 and caspase-7 by procaspase-9 (Scaffidi 
et al., 1998; Scaffidi et al., 1999). 
In addition to apoptosis, caspase-8 has a role in 
programmed necrosis (necroptosis) as well. 
Caspase-8 can be recruited to the necroptotic 
complexes (necrosome or ripoptosome) together 
with RIP1, RIP3 and FADD.  
 
Chromosomal location of CASP8 and nearby genes. 
 
It would then cleave RIP1 and RIP3, and therefore 
block necroptosis (Stupack et al., 2006; Feoktistova 
et al., 2011; Tenev et al., 2011). 
Caspase-8 also has an essential role for NF-kB 
signaling via many different stimuli including 
CD95, TRAIL, TCR and TLR stimulations 
(Kataoka and Tschopp, 2004; Dohrman et al., 2005; 
Su et al., 2005; Lemmers et al., 2007; Grunert et al., 
2012).  
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Schematic representation of the structure of the 54kb CASP8 gene, which contains 10 exons and can be transcribed into 6 
alternative splice variants. 
 
 
Interestingly, although the activation of procaspase-
8 to p102-p182 heterotetramer is necessary for 
MAPK signaling (Kober et al., 2011), it is not 
necessary for NF-kB signaling upon CD95 
stimulation (Neumann et al., 2010). 
Caspase-8 has been also reported to affect 
metastasis. Interestingly, although loss of caspase-8 
potentiates metastasis, under conditions where 
apoptosis is compromised, caspase-8 can promote 
tumor cell migration and metastasis (Stupack et al., 
2006; Barbero et al., 2009). 
Homology 
Caspase-10, FADD, c-FLIP. 
Mutations 
Germinal 
A homozygous C to T mutation at residue 248 leads 
to familial autoimmune lymphoproliferative 
syndrome type 2B. 
Somatic 
Various somatic mutations of CASP8 are identified 
in different carcinomas. Mutations are observed at 
different parts of caspase-8, but they all lead to a 
catalytically inactive form. 
- Hepatocellular carcinoma: CASP8 is frequently 
inactivated by the frameshift somatic mutation 
1225-1226delTG in hepatocellular carcinomas, 
resulting in a premature termination of amino-acid 
synthesis in the p10 protease subunit (Soung et al., 
2005b). 
- Gastric carcinoma: Inactivating CASP8 mutations 
are detected at different sites in about 10% of 
advanced gastric carcinomas (Soung et al., 2005a). 
- Colorectal carcinoma: Inactivating CASP8 
mutations are detected at different sites in about 5% 
of invasive colorectal carcinomas (Kim et al., 
2003). 
- Vulvar squamous carcinoma: Deletion of leucine 
62 (∆Leu62casp-8) is detected in A431 human 
vulvar squamous carcinoma cells. ∆Leu62casp-8  
has a shorter half-life than wild-type caspase-8 and 
cannot interact with caspase-8 or FADD; therefore 
lost its proapoptotic activity (Liu et al., 2002). 
- Head and neck carcinoma: A mutation was 
detected in the tumor cells from head and neck 
carcinoma that modifies the stop codon and 
lengthening the protein by 88 amino acids 
(Mandruzzato et al., 1997). 
- Neuroblastoma : An Alanine to Valine missense 
mutation was detected at codon 96 in a 
neuroblastoma sample which lacks CASP8 mRNA 




Hepatocellular carcinoma accounts for the majority 
of liver cancers. Mostly, it is secondary to cirrhosis, 
which is caused mainly by alcohol abuse or 
hepatitis B/C infections. A somatic mutation in 
CASP8 leading to deletion of the bases 1225-1226 
was detected in 9 out of 69 hepatocellular 
carcinoma samples from unrelated patients. This 
deletion results in a frameshift and therefore 
premature termination of amino-acid synthesis in 
the p10 protease subunit, consequently inactivating 
caspase-8 (Soung et al., 2005b). 
Gastric carcinoma 
Disease 
Gastric carcinomas arise from the epithelium of the 
stomach. In a study by Soung and colleagues 
(Soung et al., 2005a), 122 advanced gastric 
carcinoma samples were analyzed for mutations in 
the coding region and the exon-intron junctions of 
CASP8 gene by PCR-SSCP analysis. In 13 
samples, mutations in caspase-8 were found. All 
mutants were still expressed at a similar level 
compared to wild-type caspase-8, however, when 
transfected into cell lines, all mutants except one 
showed defects in apoptosis. 
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Involvement of procaspase-8 in death-receptor signaling. (A) Procaspase-8 is recruited to the CD95 or TRAIL DISC through 
the adaptor protein FADD. Upon activation of TNF, procaspase-8 is recruited through FADD and TRADD. For activation, 
procaspase-8 requires dimerization and internal cleavage. The major function of procaspase-8 in DR signaling is induction of 
apoptosis, but it also regulates necroptosis or NF-kB via RIP1/RIP3 and c-FLIP(L). (B) Procaspase-8 consists of a prodomain 
harboring tandem death effector domains (DED) followed by one large (p18) and one small (p10) catalytic subunit. Cleavage 
between p18 and p10 generates the intermediate p43/p41 which is further processed to the fully active form by cleavage 





Colorectal cancer arises from colon, rectum or 
appendix. In the analysis of 82 colorectal adenomas 
and 98 invasive colorectal carcinomas, 5 mutations 
were detected only in the colorectal carcinomas but 
not in the adenomas. 3 out of 5 of these mutations 
acted in a dominant negative manner and 
suppressed apoptosis (Kim et al., 2003). 
Vulvar squamous carcinoma 
Disease 
In the analysis of A431 human vulvar squamous 
carcinoma cells, a mutation in CASP8 leading to 
deletion of leucine 62 was detected. This mutant 
version of caspase-8 retained its enzymatic activity, 
however, it lost the ability to interact with itself, 
wild-type caspase-8 or FADD and therefore lost its 
proapoptotic activity (Liu et al., 2002). 
Head and neck carcinoma 
Disease 
Head and neck carcinomas start in the lip, oral 
cavity, nasal cavity, paranasal sinuses, pharynx, or 
larynx and the majority (90%) originates from the 
epithelium, therefore named squamous cell 
carcinomas. A mutation in CASP8 was detected in 
the cells from a tumor relapse resected from the oral 
cavity of a late-stage squamous cell carcinoma 
patient. This mutation was found to modify the stop 
codon and add an Alu repeat to the coding region. 
Therefore, the mutant protein is 88 amino acids 
longer than the wild type and cannot efficiently act 
as an apoptotic protein (Mandruzzato et al., 1997). 
Neuroblastoma 
Disease 
Neuroblastoma arises from immature nerve cells. It 
is mainly localized to adrenal medulla. In a study 
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where human neuroblastoma cells were transferred 
to chick chorioallantoic membrane, tumor 
development was monitored.  
Although presence or lack of caspase-8 did not 
change primary tumor growth, metastasis was 
highly promoted in the tumors lacking caspase-8 
due to impaired programmed cell death (Stupack et 
al., 2006).  
In a similar study, tumor cells additionally lacking 
caspase-3 were used to test non-apoptotic effects of 
caspase-8 on neuroblastoma metastasis. 
Interestingly, tumors lacking only caspase-3 
metastasized more efficiently than tumors lacking 
both caspases, pointing out that caspase-8 also 
shows non-apoptotic properties such as enhancing 
cell migration (Barbero et al., 2009). 
Silencing of caspase-8 was also observed in human 
neuroblastoma samples. In two studies by Takita 
and colleagues, 11 out of 15 and 19 out of 27 
neuroblastoma samples did not express caspase-8, 
detected by real-time PCR (Takita et al., 2000; 
Takita et al., 2001).  
Furthermore, a missense mutation was detected at 
codon 96 in one of the samples lacking caspase-8 
expression (Takita et al., 2000). 
Furthermore, silencing of CASP8 in neuroblastoma 
was found to be associated with MYCN 
amplification. 10 out of 16 patients with MYCN 
amplification had completely methylated CASP8 
alleles opposed to only 1 out of 26 patients without 
MYCN amplification.  
Interestingly, one patient among these 42 patients 




Medulloblastoma is a tumor of the brain that 
originates in the cerebellum or posterior fossa. In 
one study of medulloblastoma, 14 out of 27 tumors 
were identified to have lost CASP8 mRNA 
expression (Zuzak et al., 2002). Furthermore, 
another study showed that CASP8 expression was 
reversely correlating with the disease. The 5-year 
cumulative progression-free survival rate of the 
patients with weak CASP8 expression was 31%, 
and with moderate/strong caspase-8 expression 
73% (Pingoud-Meier et al., 2003). 
Small cell lung carcinoma 
Disease 
Small cell lung carcinomas commonly originate 
from the lung, although rarely can originate also 
from cervix, prostate or gastrointesinal tract. In this 
carcinoma, tumor cells are much smaller than 
normal cells with almost no cytoplasm. In one 
study, 13 out of 25 small cell lung carcinoma 
samples showed silencing of CASP8 due to 
methylation (Hopkins-Donaldson et al., 2003). 
Autoimmune lymphoproliferative 
syndrome type 2B 
Disease 
A homozygous C to T mutation in caspase-8 at 
residue 248 in the p18 protease subunit leads to 
autoimmune lymphoproliferative syndrome type 2B 
(Chun et al., 2002). 
Autoimmune Lymphoproliferative Syndrome Type 
2B is an autosomal dominant disease where there 
are defects in activation of T cells, B cells, and 
natural killer cells of the patients as well as in 
CD95-mediated apoptosis. Patients have 
lymphoproliferation and thus lymphadenopathy, 
splenomegaly and autoimmunity. 
References 
Muzio M, Chinnaiyan AM, Kischkel FC et al.. FLICE, a 
novel FADD-homologous ICE/CED-3-like protease, is 
recruited to the CD95 (Fas/APO-1) death--inducing 
signaling complex. Cell. 1996 Jun 14;85(6):817-27 
Mandruzzato S, Brasseur F, Andry G, Boon T, van der 
Bruggen P. A CASP-8 mutation recognized by cytolytic T 
lymphocytes on a human head and neck carcinoma. J Exp 
Med. 1997 Aug 29;186(5):785-93 
Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann 
M, Krammer PH, Peter ME. FLICE is activated by 
association with the CD95 death-inducing signaling 
complex (DISC). EMBO J. 1997 May 15;16(10):2794-804 
Scaffidi C, Medema JP, Krammer PH, Peter ME. FLICE is 
predominantly expressed as two functionally active 
isoforms, caspase-8/a and caspase-8/b. J Biol Chem. 
1997 Oct 24;272(43):26953-8 
Scaffidi C, Fulda S, Srinivasan A et al.. Two CD95 (APO-
1/Fas) signaling pathways. EMBO J. 1998 Mar 
16;17(6):1675-87 
Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, 
Peter ME. Differential modulation of apoptosis sensitivity in 
CD95 type I and type II cells. J Biol Chem. 1999 Aug 
6;274(32):22532-8 
Horiuchi T, Himeji D, Tsukamoto H et al.. Dominant 
expression of a novel splice variant of caspase-8 in human 
peripheral blood lymphocytes. Biochem Biophys Res 
Commun. 2000 Jun 16;272(3):877-81 
Takita J, Yang HW, Bessho F, Hanada R, Yamamoto K, 
Kidd V, Teitz T, Wei T, Hayashi Y. Absent or reduced 
expression of the caspase 8 gene occurs frequently in 
neuroblastoma, but not commonly in Ewing sarcoma or 
rhabdomyosarcoma. Med Pediatr Oncol. 2000 
Dec;35(6):541-3 
Teitz T, Wei T, Valentine MB, Vanin EF et al.. Caspase 8 
is deleted or silenced preferentially in childhood 
neuroblastomas with amplification of MYCN. Nat Med. 
2000 May;6(5):529-35 
Qin ZH, Wang Y, Kikly KK, Sapp E, Kegel KB, Aronin N, 
DiFiglia M. Pro-caspase-8 is predominantly localized in 
mitochondria and released into cytoplasm upon apoptotic 
stimulation. J Biol Chem. 2001 Mar 16;276(11):8079-86 
Takita J, Yang HW, Chen YY, Hanada R et al.. Allelic 
imbalance on chromosome 2q and alterations of the 
caspase 8 gene in neuroblastoma. Oncogene. 2001 Jul 
19;20(32):4424-32 






Atlas Genet Cytogenet Oncol Haematol. 2014; 18(6) 377 
Benchoua A, Couriaud C, Guégan C, Tartier L et al.. 
Active caspase-8 translocates into the nucleus of apoptotic 
cells to inactivate poly(ADP-ribose) polymerase-2. J Biol 
Chem. 2002 Sep 13;277(37):34217-22 
Chun HJ, Zheng L, Ahmad M, Wang J et al.. Pleiotropic 
defects in lymphocyte activation caused by caspase-8 
mutations lead to human immunodeficiency. Nature. 2002 
Sep 26;419(6905):395-9 
Himeji D, Horiuchi T, Tsukamoto H, Hayashi K, Watanabe 
T, Harada M. Characterization of caspase-8L: a novel 
isoform of caspase-8 that behaves as an inhibitor of the 
caspase cascade. Blood. 2002 Jun 1;99(11):4070-8 
Liu B, Peng D, Lu Y, Jin W, Fan Z. A novel single amino 
acid deletion caspase-8 mutant in cancer cells that lost 
proapoptotic activity. J Biol Chem. 2002 Aug 
16;277(33):30159-64 
Zuzak TJ, Steinhoff DF, Sutton LN, Phillips PC, Eggert A, 
Grotzer MA. Loss of caspase-8 mRNA expression is 
common in childhood primitive neuroectodermal brain 
tumour/medulloblastoma. Eur J Cancer. 2002 
Jan;38(1):83-91 
Hopkins-Donaldson S, Ziegler A, Kurtz S et al.. Silencing 
of death receptor and caspase-8 expression in small cell 
lung carcinoma cell lines and tumors by DNA methylation. 
Cell Death Differ. 2003 Mar;10(3):356-64 
Kim HS, Lee JW, Soung YH, Park WS, Kim SY et al.. 
Inactivating mutations of caspase-8 gene in colorectal 
carcinomas. Gastroenterology. 2003 Sep;125(3):708-15 
Pingoud-Meier C, Lang D, Janss AJ, Rorke LB et al.. Loss 
of caspase-8 protein expression correlates with 
unfavorable survival outcome in childhood 
medulloblastoma. Clin Cancer Res. 2003 Dec 
15;9(17):6401-9 
Chandra D, Choy G, Deng X, Bhatia B, Daniel P, Tang 
DG. Association of active caspase 8 with the mitochondrial 
membrane during apoptosis: potential roles in cleaving 
BAP31 and caspase 3 and mediating mitochondrion-
endoplasmic reticulum cross talk in etoposide-induced cell 
death. Mol Cell Biol. 2004 Aug;24(15):6592-607 
Kataoka T, Tschopp J. N-terminal fragment of c-FLIP(L) 
processed by caspase 8 specifically interacts with TRAF2 
and induces activation of the NF-kappaB signaling 
pathway. Mol Cell Biol. 2004 Apr;24(7):2627-36 
Dohrman A, Kataoka T, Cuenin S, Russell JQ, Tschopp J, 
Budd RC. Cellular FLIP (long form) regulates CD8+ T cell 
activation through caspase-8-dependent NF-kappa B 
activation. J Immunol. 2005 May 1;174(9):5270-8 
Soung YH, Lee JW, Kim SY, Jang J, Park YG et al.. 
CASPASE-8 gene is inactivated by somatic mutations in 
gastric carcinomas. Cancer Res. 2005a Feb 1;65(3):815-
21 
Soung YH, Lee JW, Kim SY, Sung YJ, Park WS, Nam SW, 
Kim SH, Lee JY, Yoo NJ, Lee SH. Caspase-8 gene is 
frequently inactivated by the frameshift somatic mutation 
1225_1226delTG in hepatocellular carcinomas. Oncogene. 
2005b Jan 6;24(1):141-7 
Su H, Bidère N, Zheng L, Cubre A, Sakai K, Dale J, 
Salmena L, Hakem R, Straus S, Lenardo M. Requirement 
for caspase-8 in NF-kappaB activation by antigen receptor. 
Science. 2005 Mar 4;307(5714):1465-8 
Stupack DG, Teitz T, Potter MD, Mikolon D et al.. 
Potentiation of neuroblastoma metastasis by loss of  
 
caspase-8. Nature. 2006 Jan 5;439(7072):95-9 
Lemmers B, Salmena L, Bidère N, Su H et al.. Essential 
role for caspase-8 in Toll-like receptors and NFkappaB 
signaling. J Biol Chem. 2007 Mar 9;282(10):7416-23 
Yao Z, Duan S, Hou D, Heese K, Wu M. Death effector 
domain DEDa, a self-cleaved product of caspase-8/Mch5, 
translocates to the nucleus by binding to ERK1/2 and 
upregulates procaspase-8 expression via a p53-dependent 
mechanism. EMBO J. 2007 Feb 21;26(4):1068-80 
Barbero S, Mielgo A, Torres V, Teitz T et al.. Caspase-8 
association with the focal adhesion complex promotes 
tumor cell migration and metastasis. Cancer Res. 2009 
May 1;69(9):3755-63 
Hoffmann JC, Pappa A, Krammer PH, Lavrik IN. A new C-
terminal cleavage product of procaspase-8, p30, defines 
an alternative pathway of procaspase-8 activation. Mol Cell 
Biol. 2009 Aug;29(16):4431-40 
Mielgo A, Torres VA, Clair K, Barbero S, Stupack DG. 
Paclitaxel promotes a caspase 8-mediated apoptosis 
through death effector domain association with 
microtubules. Oncogene. 2009 Oct 8;28(40):3551-62 
Xu Z, Tang K, Wang M, Rao Q, Liu B, Wang J. A new 
caspase-8 isoform caspase-8s increased sensitivity to 
apoptosis in Jurkat cells. J Biomed Biotechnol. 
2009;2009:930462 
Neumann L, Pforr C, Beaudouin J, Pappa A, Fricker N, 
Krammer PH, Lavrik IN, Eils R. Dynamics within the CD95 
death-inducing signaling complex decide life and death of 
cells. Mol Syst Biol. 2010;6:352 
Feoktistova M, Geserick P, Kellert B et al.. cIAPs block 
Ripoptosome formation, a RIP1/caspase-8 containing 
intracellular cell death complex differentially regulated by 
cFLIP isoforms. Mol Cell. 2011 Aug 5;43(3):449-63 
Kober AM, Legewie S, Pforr C, Fricker N, Eils R, Krammer 
PH, Lavrik IN. Caspase-8 activity has an essential role in 
CD95/Fas-mediated MAPK activation. Cell Death Dis. 
2011 Oct 6;2:e212 
McCall MN, Uppal K, Jaffee HA, Zilliox MJ, Irizarry RA. 
The Gene Expression Barcode: leveraging public data 
repositories to begin cataloging the human and murine 
transcriptomes. Nucleic Acids Res. 2011 Jan;39(Database 
issue):D1011-5 
Tenev T, Bianchi K, Darding M, Broemer M et al.. The 
Ripoptosome, a signaling platform that assembles in 
response to genotoxic stress and loss of IAPs. Mol Cell. 
2011 Aug 5;43(3):432-48 
Grunert M, Gottschalk K, Kapahnke J et al.. The adaptor 
protein FADD and the initiator caspase-8 mediate 
activation of NF-κB by TRAIL. Cell Death Dis. 2012 Oct 
25;3:e414 
Lavrik IN, Krammer PH. Regulation of CD95/Fas signaling 
at the DISC. Cell Death Differ. 2012 Jan;19(1):36-41 
Schleich K, Warnken U, Fricker N, Oztürk S et al.. 
Stoichiometry of the CD95 death-inducing signaling 
complex: experimental and modeling evidence for a death 
effector domain chain model. Mol Cell. 2012 Jul 
27;47(2):306-19 
This article should be referenced as such: 
Öztürk S, Schleich K, Lavrik IN. CASP8 (Caspase 8, 
Apoptosis-Related Cysteine Peptidase). Atlas Genet 
Cytogenet Oncol Haematol. 2014; 18(6):372-377. 
